Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ADL 5859

Drug Profile

ADL 5859

Alternative Names: ADL-5859; PF-04856880; PF-4856880

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adolor Corporation
  • Developer Adolor Corporation; Pfizer
  • Class Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid delta receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Dental pain; Inflammatory pain; Neuropathic pain

Most Recent Events

  • 18 Jun 2010 Efficacy and adverse events data from a phase IIa trial in Inflammatory pain (osteoarthritis of knee) released by (Adolor Corporation)
  • 30 Oct 2009 Adolor and Pfizer initiate a phase IIa proof-of-concept trial for patients with osteoarthritis in the US
  • 15 Dec 2007 Phase-II clinical trials in Neuropathic pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top